ImmunityBio, Inc. IBRX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
Based on trailing twelve months.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s EBITDA margin?
- ImmunityBio, Inc. (IBRX) reported EBITDA margin of -174% in Q1 2026.
- How has ImmunityBio, Inc.'s EBITDA margin changed year-over-year?
- ImmunityBio, Inc.'s EBITDA margin increased by 81.7% year-over-year, from -949.9% to -174%.
- What is the long-term trend for ImmunityBio, Inc.'s EBITDA margin?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s EBITDA margin has grown at a -60.5% compound annual growth rate (CAGR), from -22,204.7% to -212.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.